Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Pharmacodynamic (PD) evaluatio...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Pharmacodynamic (PD) evaluation of LY2181308 in patients with metastatic malignancies
Bibliographic Details
Main Authors:
Talbot, D
,
Davies, J
,
Olsen, A
,
Andre, V
,
Lahn, M
,
Powell, E
,
Kadam, S
,
de Bono, J
,
McHugh, P
,
Ranson, M
Format:
Conference item
Published:
2009
Holdings
Description
Similar Items
Staff View
Similar Items
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study.
by: Talbot, D, et al.
Published: (2010)
First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin
by: Talbot, D, et al.
Published: (2008)
Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients.
by: Saleem, A, et al.
Published: (2011)
Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma.
by: Herrington, W, et al.
Published: (2011)
A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line treatment of patients with non-small cell lung cancer (NSCLC) using change in tumor size (CTS)
by: Talbot, D, et al.
Published: (2013)